Effectiveness of ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor: A multi-centre comparative study

被引：0
|
作者：
Alric, H. [1 ]
Amiot, A. [2 ]
Kirchgesner, J. [3 ]
Treton, X. [4 ]
Allez, M. [5 ]
Bouhnik, Y. [4 ]
Beaugerie, L. [3 ]
Carbonnel, F. [1 ]
Meyer, A. [1 ]
机构：
[1] Hop Bicetre, Serv Gastroenterol, Le Kremlin Bicetre, France
[2] Hop Henri Mondor, Serv Gastroenterol, Creteil, France
[3] Hop St Antoine, Serv Gastroenterol, Paris, France
[4] Hop Beaujon, Serv Gastroenterol & Assistance Nutr, Clichy, France
[5] Hop St Louis, Serv Gastroenterol, Paris, France
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP80
引用
收藏
页码：S118 / S120
页数：3
相关论文
共 50 条
  • [1] The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor
    Alric, Hadrien
    Amiot, Aurelien
    Kirchgesner, Julien
    Treton, Xavier
    Allez, Mathieu
    Bouhnik, Yoram
    Beaugerie, Laurent
    Carbonnel, Franck
    Meyer, Antoine
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (10) : 948 - 957
  • [2] COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB AND USTEKINUMAB IN ANTI-TNF REFRACTORY CROHN'S DISEASE: MULTI-CENTRE RETROSPECTIVE COHORT STUDY
    Townsend, Tristan
    Razanskaite, Violeta
    Michail, Stephanie
    Morgan, James
    Davies, Michael
    Storey, Daniel
    Watters, Christopher
    Penman, Douglas
    Swaminathan, Mira
    Reilly, Ian
    Flanagan, Paul
    Subramanian, Sreedhar
    GUT, 2021, 70 : A127 - A127
  • [3] MULTI-CENTRE COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB AND USTEKINUMAB AS INDUCTION THERAPY IN ANTI-TNF REFRACTORY CROHN'S DISEASE
    Razanskaite, Violeta
    Michail, Stephanie
    Morgan, James
    Davies, Michael
    Storey, Daneil
    Watters, Christopher
    Penman, Douglas
    Swaminathan, Mira
    Sabine, Joseph
    Chapman, Adam
    Reilly, Ian
    Flanagan, Paul
    Bodger, Keith
    Subramanian, Sreedhar
    GUT, 2019, 68 : A100 - A100
  • [4] Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor
    Parrot, Laurene
    Dong, Catherine
    Carbonnel, Franck
    Meyer, Antoine
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (04) : 380 - 388
  • [5] Comparative effectiveness of vedolizumab and ustekinumab as induction therapy in anti-TNF refractory Crohn's disease: a multi-centre retrospective cohort study
    Townsend, T.
    Razanskaite, V.
    Michail, S.
    Morgan, J.
    Davies, M.
    Storey, D.
    Watters, C.
    Penman, D.
    Swaminathan, M.
    Sabine, J.
    Chapman, A.
    Vyas, A.
    Reilly, I.
    Flanagan, P.
    Bodger, K.
    Subramanian, S.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S407 - S408
  • [6] Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy
    Manlay, Luc
    Boschetti, Gilles
    Pereira, Bruno
    Flourie, Bernard
    Dapoigny, Michel
    Reymond, Maud
    Sollelis, Elisa
    Gay, Claire
    Boube, Mathilde
    Buisson, Anthony
    Nancey, Stephane
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (12) : 1289 - 1299
  • [7] Efficacy and safety of ustekinumab in patients with Crohn's disease refractory to anti-tumour necrosis factor: real clinical practice
    Saiz Chumillas, R. M.
    Alba Hernandez, L.
    Chivato Martin-Falquina, I.
    Badia Aranda, E.
    Arias Garcia, M. L.
    Sicilia Aladren, B.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S400 - S401
  • [8] Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
    Bohm, Matthew
    Xu, Ronghui
    Zhang, Yiran
    Varma, Sashidhar
    Fischer, Monika
    Kochhar, Gursimran
    Boland, Brigid
    Singh, Siddharth
    Hirten, Robert
    Ungaro, Ryan
    Shmidt, Eugenia
    Lasch, Karen
    Jairaith, Vipul
    Hudesman, David
    Chang, Shannon
    Lukin, Dana
    Swaminath, Arun
    Sands, Bruce E.
    Colombel, Jean-Frederic
    Kane, Sunanda
    Loftus, Edward V., Jr.
    Shen, Bo
    Siegel, Corey A.
    Sandborn, William J.
    Dulai, Parambir S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (04) : 669 - 681
  • [9] Effectiveness and safety of Ustekinumab for induction of remission in patients with Crohn's disease: a multi-centre Israeli study
    Shitrit, A. Bar-Gil
    Siterman, M.
    Waterman, M.
    Hirsh, A.
    Khoury, T.
    Schwartz, D.
    Zittan, E.
    Adler, J.
    Koslowsky, B.
    Avni-Biron, I.
    Chowers, Y.
    Ron, Y.
    Israeli, E.
    Ungar, B.
    Yanai, H.
    Maharshak, N.
    Ben-Horin, S.
    Ben-Ya'acov, A.
    Eliakim, R.
    Dotan, I.
    Goldin, E.
    Kopylov, U.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S399 - S400
  • [10] Effectiveness of ustekinumab after vedolizumab failure in patients with anti-TNF-refractory Crohn's disease
    Dussias, N.
    Rizzello, F.
    Calabrese, C.
    Passino, A. Sanna
    Melotti, L.
    Scaioli, E.
    Belluzzi, A.
    Gionchetti, P.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S528 - S528
12345